Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.44 |
| ▸ | SMO | Q99835 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL977050 | 0.99 | PARP10 (0.51) | PARP10DRD4NPC1RAB9AMAPT | |
| SCHEMBL976548 | 0.97 | PARP10 (0.51) | PARP10DRD4NPC1RAB9AMAPT | |
| SCHEMBL975686 | 0.90 | PARP10 (0.48) | PARP10DRD4MAPK14SMOMEN1 | |
| SCHEMBL975297 | 0.90 | PARP10 (0.48) | PARP10DRD4NPC1RAB9AMAPK14 | |
| SCHEMBL975183 | 0.89 | PARP10 (0.56) | PARP10MAPTMAPK14SMOSMN1; SMN2 | |
| SCHEMBL977351 | 0.88 | PARP10 (0.52) | PARP10MAPK14SMOSMN1; SMN2MEN1 | |
| SCHEMBL977936 | 0.87 | SMN1; SMN2 (0.49) | PARP10NPC1RAB9AMAPK14SMO | |
| SCHEMBL975604 | 0.86 | PARP10 (0.53) | PARP10MAPK14SMOSMN1; SMN2MEN1 | |
| SCHEMBL976551 | 0.85 | PARP10 (0.56) | PARP10ALOX5MAPK14SMOSMN1; SMN2 | |
| SCHEMBL975447 | 0.84 | PARP10 (0.53) | PARP10MAPK14SMOSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003815-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES | MERCK & CO., INC. | 2011-01-06 | — | — | US | disclosed |
| EP-2209761-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES | Merck Sharp & Dohme Corp. (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009048547-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES | MERCK & CO., INC. (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003815-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES | PTGIS, PTGS1, LTC4S | PARP10 567/4885DRD4 2640/4885NPC1 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.